FENNEC director granted options for 20,000 shares

FENNEC PHARMACEUTICALS INC. director Chris A. Rallis received a compensation-related stock option grant.

Rhea-AI Filing Summary

FENNEC PHARMACEUTICALS INC. director Chris A. Rallis received a compensation-related stock option grant. On June 10, 2026, he was granted a non-qualified option to purchase 20,000 common shares at an exercise price of $8.70 per share under the company’s Equity Incentive Plan.

The option is 100% vested on the grant date and expires on June 10, 2036. Following this award, Rallis holds stock options for a total of 200,000 shares, according to the filing. This is an equity grant, not an open-market share purchase.

Insider Trade Summary

Grant/Award: 20,000 shares

Grant/Award 1 txn

Insider RALLIS CHRIS A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	20,000	$8.70	$174K

Holdings After Transaction: Stock Option — 200,000 contracts (Direct)

Footnotes (2)

1. F1. On June 10, 2026, Chris Rallis was granted a non-qualified stock option to purchase 20,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan.
2. F2. The option is 100% vested on date of grant.

Key Figures

Option grant size: 20,000 shares Exercise price: $8.70 per share Total options after grant: 200,000 shares +2 more

5 metrics

Option grant size 20,000 shares Non-qualified stock option granted June 10, 2026

Exercise price $8.70 per share Strike price for 20,000-share option grant

Total options after grant 200,000 shares Derivative securities beneficially owned following transaction

Vesting 100% on grant date Option fully vested June 10, 2026

Option expiration June 10, 2036 Expiration date of non-qualified stock option

Key Terms

non-qualified stock option, Equity Incentive Plan, grant, award, or other acquisition

3 terms

non-qualified stock option financial

"Chris Rallis was granted a non-qualified stock option to purchase 20,000 shares"

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

Equity Incentive Plan financial

"20,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did FENNEC PHARMACEUTICALS (FENC) disclose about Chris Rallis in this Form 4?

FENNEC PHARMACEUTICALS reported that director Chris A. Rallis received a non-qualified stock option grant for 20,000 common shares on June 10, 2026. The option was issued under the company’s Equity Incentive Plan as part of his compensation, not as an open-market purchase.

How many FENC shares are covered by Chris Rallis’s new stock option grant?

The new option grant allows Chris A. Rallis to purchase 20,000 FENNEC PHARMACEUTICALS common shares. This award increases his total stock option holdings to 200,000 shares, based on the total shares following the transaction disclosed in the Form 4 filing.

What is the exercise price of Chris Rallis’s FENC stock option grant?

The non-qualified stock option granted to Chris A. Rallis carries an exercise price of $8.70 per share. This means he can purchase up to 20,000 FENNEC PHARMACEUTICALS common shares at $8.70, regardless of the future market price, subject to the option’s terms.

When do Chris Rallis’s newly granted FENC stock options vest and expire?

Chris A. Rallis’s stock option is 100% vested on the June 10, 2026 grant date, giving him immediate exercisability. The option expires on June 10, 2036, providing a 10-year window during which he can choose to exercise and purchase the underlying shares.

How many FENC stock options does Chris Rallis hold after this transaction?

After this grant, Chris A. Rallis holds stock options covering a total of 200,000 FENNEC PHARMACEUTICALS common shares. This figure is reported as the total number of derivative securities beneficially owned following the transaction in the Form 4 insider filing.

Is Chris Rallis’s FENC stock option grant an open-market purchase of shares?

No, the transaction is a non-qualified stock option grant, categorized as a grant, award, or other acquisition. It provides Chris A. Rallis the right to purchase 20,000 FENNEC PHARMACEUTICALS shares at $8.70, rather than reflecting an immediate open-market share purchase.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/10/2026 - 05:24 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RALLIS CHRIS A

(Last) (First) (Middle)

C/O FENNEC PHARMACEUTICALS, INC.

PO BOX 13628, 68 TW ALEXANDER DRIVE

(Street)

RESEARCH TRIANGLE PARK NORTH CAROLINA 27709

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
FENNEC PHARMACEUTICALS INC. [ FENC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option(1)	$8.7	06/10/2026		A		20,000		06/10/2026(2)	06/10/2036	Common shares	20,000	$8.7	200,000	D

Explanation of Responses:

1. On June 10, 2026, Chris Rallis was granted a non-qualified stock option to purchase 20,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan.

2. The option is 100% vested on date of grant.

	/s/ Chris Rallis	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)